R1 RCM Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Los beneficios de R1 RCM han disminuido a una tasa media anual de -4.1%, mientras que en la industria Healthcare los beneficios crecieron en un 7.1% anualmente. Los ingresos han ido creciendo a una tasa media de 16.8% al año. La rentabilidad financiera de R1 RCM es de 0.1%, y sus márgenes netos son de 0.1%.

Información clave

-4.1%

Tasa de crecimiento de los beneficios

5.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	8.5%
Tasa de crecimiento de los ingresos	16.8%
Rentabilidad financiera	0.1%
Margen neto	0.1%
Próxima actualización de resultados	08 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

Jun 05

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 06

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

Mar 17

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

Jan 06

R1 RCM slides 7% on secondary stock offering by selling shareholder

Sep 08

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Aug 11

R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line

Aug 03

R1 RCM: Long-Term Growth Story Intact Following Cloudmed Acquisition

Jul 19

News Flash: Analysts Just Made A Meaningful Upgrade To Their R1 RCM Inc. (NASDAQ:RCM) Forecasts

Jun 30

R1 RCM draws bullish views at Barclays on Cloudmed acquisition

Jun 29

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero R1 RCM. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:RCM Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	2,254	3	220
30 Sep 23	2,212	-35	219
30 Jun 23	2,135	-65	222
31 Mar 23	1,966	-91	190
31 Dec 22	1,806	-63	173
30 Sep 22	1,672	-1	152
30 Jun 22	1,556	45	127
31 Mar 22	1,518	91	126
31 Dec 21	1,475	-505	122
30 Sep 21	1,404	-495	116
30 Jun 21	1,332	-512	108
31 Mar 21	1,293	-526	103
31 Dec 20	1,270	47	101
30 Sep 20	1,256	14	102
30 Jun 20	1,250	16	105
31 Mar 20	1,231	3	108
31 Dec 19	1,186	-9	105
30 Sep 19	1,135	-22	106
30 Jun 19	1,084	-42	107
31 Mar 19	997	-41	104
31 Dec 18	869	-64	98
30 Sep 18	746	-99	84
30 Jun 18	619	-88	69
31 Mar 18	510	-92	59
31 Dec 17	450	-76	56
30 Sep 17	416	-28	60
30 Jun 17	418	-3	65
31 Mar 17	327	-36	71
31 Dec 16	593	65	74
30 Sep 16	555	68	73
30 Jun 16	445	17	75
31 Mar 16	458	35	78
31 Dec 15	117	-84	75
30 Sep 15	96	-107	77
30 Jun 15	171	-65	72
31 Mar 15	208	-55	71
31 Dec 14	210	-80	76
30 Sep 14	247	-56	70
30 Jun 14	174	-103	76
31 Mar 14	490	102	75
31 Dec 13	505	130	80
30 Sep 13	-220	0	-9
30 Jun 13	-16	41	19

Ingresos de calidad: RCM tiene un gran one-off loss de $117.3M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: RCM pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: RCM ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de -4.1% al año.

Acelerando crecimiento: RCM ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: RCM ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (7.3%).

R1 RCM Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS misses analyst expectations

R1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)

R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)

Recent updates

R1 RCM Inc., Annual General Meeting, May 22, 2024

R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024

Consensus EPS estimates upgraded to US$0.0021 loss

Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment

New minor risk - Earnings quality

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024

New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion.

Full year 2023 earnings: EPS misses analyst expectations

Coliseum Capital Issues an Open Letter to the Board of R1 RCM

R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting Officer

R1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health for $680 million.

R1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024

R1 RCM Inc. Appoints Clay Ashdown as Director

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Inc. announced delayed 10-Q filing

Price target decreased by 8.8% to US$19.53

R1 RCM Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)

Now 26% undervalued after recent price drop

R1 RCM Inc. Announces Janie Wade Resigns from its Board of Directors

Now 20% undervalued after recent price drop

R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of R1 RCM Inc. (NASDAQ:RCM)

Returns At R1 RCM (NASDAQ:RCM) Are On The Way Up

Lead Independent Director notifies of intention to sell stock

Price target increased by 7.8% to US$21.70

R1 RCM Inc. Provides Earnings Guidance for the Year of 2023

Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)

Is Now An Opportune Moment To Examine R1 RCM Inc. (NASDAQ:RCM)?

R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023

Why We're Not Concerned About R1 RCM Inc.'s (NASDAQ:RCM) Share Price

Senior VP recently sold US$487k worth of stock

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

President recently sold US$327k worth of stock

President notifies of intention to sell stock

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

R1 RCM Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

CEO & Director recently bought US$1.0m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023

Price target increased by 7.3% to US$16.18

R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023

Consensus forecasts updated

R1 RCM Inc. Announces Chief Financial Officer Changes

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

R1 RCM Inc. Appoints Janie Wade as a Director of the Company, Effective January 1, 2023

R1 RCM Inc. Announces Retirement of Albert Zimmerli from the Board of Directors, Effective January 1, 2023

Price target decreased to US$15.55

Price target decreased to US$27.82

R1 RCM Inc. Provides Earnings Guidance for the Year 2022

R1 RCM Inc. to Report Q3, 2022 Results on Nov 08, 2022

R1 RCM slides 7% on secondary stock offering by selling shareholder

Key Executive recently sold US$1.0m worth of stock

R1 RCM Inc. Appoints Brian Dean as Director

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Key Executive exercised options and sold US$1.2m worth of stock

Independent Director recently sold US$270k worth of stock

Second quarter 2022 earnings: EPS misses analyst expectations

R1 RCM Inc. Provides Revenue Guidance for the Full Year of 2022

R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line

Consensus forecasts updated

R1 RCM Inc. to Report Q2, 2022 Results on Aug 03, 2022

R1 RCM: Long-Term Growth Story Intact Following Cloudmed Acquisition

Consensus forecasts updated

Desglose de ingresos y gastos
Beta